Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levotofisopam SCHEMBL5431173 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Dextofisopam SCHEMBL236796 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Tofisopam SCHEMBL29832594 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Dextofisopam SCHEMBL29376877 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Tofisopam SCHEMBL43522 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Tofisopam SCHEMBL4585183 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| Tofisopam SCHEMBL8086894 | 1.00 | KMT2A (1.00) | KMT2APDE4AMEN1CHRM1PDE4D | |
| SCHEMBL5426026 | 0.94 | PDE4A (0.88) | KMT2APDE4AMEN1CHRM1PDE4D | |
| SCHEMBL5424919 | 0.94 | PDE4A (0.88) | KMT2APDE4AMEN1CHRM1PDE4D | |
| SCHEMBL5425481 | 0.94 | PDE4A (0.88) | KMT2APDE4AMEN1CHRM1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161628-A1 | Phosphodiesterase inhibitors | GREENPHARMA (FR) | 2007-07-12 | — | — | US | claimed |
| US-9408852-B2 | Method of lowering serum uric acid levels with (S)-tofisopam | PHARMOS CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-7265106-B2 | Method for isolating (R)-tofisopam | VELA AQUISITION CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265106-B2 | Method for isolating (R)-tofisopam | VELA AQUISITION CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070161628-A1 | Phosphodiesterase inhibitors | GREENPHARMA (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070021412-A1 | Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine | VELA PHARMACEUTICALS, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-20040254174-A1 | Method for isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | US | disclosed |
| US-20040254174-A1 | Method for isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | US | disclosed |
| WO-2004073638-A2 | METHOD OF LOWERING BODY TEMPERATURE WITH (S)-2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004050080-A1 | TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254174-A1 | Method for isolating (R)-tofisopam | AMY1A, SI, IRS1 | KMT2A 4035/4885PDE4A 4520/4885MEN1 592/4885 |
| US-20070161628-A1 | Phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | KMT2A 2209/4885PDE4A 6/4885MEN1 3432/4885 |
| US-20070021412-A1 | Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine | GABRA2, HRH2, GABRA3 | KMT2A 1803/4885PDE4A 2142/4885MEN1 4660/4885 |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | GABBR2, GABBR1, GABRB3 | KMT2A 3002/4885PDE4A 1520/4885MEN1 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.